Journal article
BASDAI versus ASDAS in evaluating axial involvement in patients with psoriatic arthritis: a pooled analysis of two phase 3 studies
Rheumatology advances in practice, v 8(2), 058
2024
PMID: 38765190
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Objective In the absence of axial psoriatic arthritis (axPsA)-specific tools, the BASDAI and Ankylosing Spondylitis Disease Activity Score (ASDAS) are used to assess axial symptoms in patients with PsA. Here, we assessed the performance of BASDAI and ASDAS in patients with PsA.Methods Patients with active PsA in DISCOVER-1 and DISCOVER-2 (ClinicalTrials.gov: NCT03162796 and NCT03158285, respectively) with or without axPsA but with available baseline BASDAI information were analysed; those with investigator-identified axial symptoms and imaging-confirmed sacroiliitis comprised the axPsA cohort. Correlations between BASDAI/ASDAS and clinical variables were assessed with Pearson's coefficient (r). Longitudinal effects of enthesitis (Leeds Enthesitis Index [LEI]), swollen joint count and presence versus absence of axPsA on BASDAI/ASDAS (normalized 0-10 scale) were analysed with mixed models for repeated measures.Results At baseline in the axPsA (n = 312) and non-axPsA (n = 124) cohorts, BASDAI scores showed no or weak correlation with swollen joint count (0.18-0.20), tender joint count (0.12-0.29), LEI (-0.04 to 0.24) and physician global assessment (0.35-0.43); moderate correlation with fatigue (both -0.56); and strong correlation with patient global assessment of disease activity (0.62-0.69) and patient-reported pain (0.66-0.70). Similar correlations were observed for ASDAS. Axial involvement versus non-involvement was associated with higher BASDAI scores and ASDAS (all beta >= 0.5), without differences between instruments; longitudinal associations between swollen joint count (beta <= 0.06)/LEI (beta <= 0.19) and BASDAI/ASDAS were clinically unimportant.Conclusion BASDAI and ASDAS performed similarly in patients with active PsA and axial involvement, independent of peripheral disease involvement, supporting their performance in assessing axial disease activity.Trial registration ClinicalTrials.gov, http://clinicaltrials.gov, NCT03162796 and NCT03158285.
What does this mean for patients?Psoriatic arthritis is a chronic inflammatory disease that impacts the joints and skin. Some patients with psoriatic arthritis may also experience inflammation of the spine and/or sacroiliac joints, also known as axial involvement. Disease severity and treatment response are often evaluated using questionnaires completed by patients and/or their health care providers. Currently, no such tools are specific for axial psoriatic arthritis. Two tools designed to monitor disease activity in patients with ankylosing spondylitis (also referred to as radiographic axial spondyloarthritis), another condition that causes inflammation in the spine, are utilized to evaluate disease activity in patients with axial psoriatic arthritis. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) measures symptoms including neck, back and hip pain; pain in other (peripheral) joints; fatigue; and morning stiffness. The Ankylosing Spondylitis Disease Activity Score (ASDAS) includes several symptoms assessed by the BASDAI and levels of C-reactive protein in the blood, an indicator of overall inflammation. In this report, the BASDAI and ASDAS were similarly able to detect changes in spine-related symptoms, independent of peripheral joint symptoms, in patients with moderately-to-highly active psoriatic arthritis. These findings support the use of these tools in assessing axial-related symptoms and contribute to ongoing efforts to define axial disease and treatment outcomes in psoriatic arthritis.
Metrics
Details
- Title
- BASDAI versus ASDAS in evaluating axial involvement in patients with psoriatic arthritis: a pooled analysis of two phase 3 studies
- Creators
- Xenofon Baraliakos (Corresponding Author) - Rheumazentrum RuhrgebietDafna D. Gladman - Toronto Western HospitalSoumya D. Chakravarty - Johnson & JohnsonCinty Gong - Johnson & JohnsonMay Shawi - JanssenEmmanouil Rampakakis - McGill UniversityMitsumasa Kishimoto - Kyorin UniversityEnrique R. Soriano - Hospital Italiano de Buenos AiresPhilip J. Mease - Swedish Medical Center
- Publication Details
- Rheumatology advances in practice, v 8(2), 058
- Publisher
- Oxford Univ Press
- Number of pages
- 8
- Grant note
- Janssen Research & Development, LLC
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Rheumatology; General Internal Medicine
- Web of Science ID
- WOS:001224473700001
- Scopus ID
- 2-s2.0-85194176946
- Other Identifier
- 991021930318504721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Industry collaboration
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Rheumatology